Gamida Cell Ltd at Jefferies Healthcare Conference Transcript

Jun 08, 2022 / 03:00PM GMT
Unidentified Participant

Good morning, and welcome to the 2022 Global Jefferies Healthcare Conference. It's my great pleasure to introduce Julian Adams from Gamida health. Over to you.

Julian Adams - Gamida Cell - CEO

Thank you. And thank you, everyone, who is joining us today. And for those of you on the webcast, welcome and good morning. We have some really great news of late at Gamida Cell. Just last week, we announced the completion of the rolling BLA submission for our lead program omidubicel, and we'll take you through that and the cadence of what's to come.

We also announced that we are now open for enrollment in our second product candidate for lymphoma, GDA-201; also received FDA clearance, and we're open for enrollment. And these are exciting times for us. There are a few forward-looking statements that I'll allow you to speed read and verify on our SEC filings.

At Gamida, there are three pillars of the NAM-enabled expanded cell pipeline. On the far left, omidubicel is our most advanced program. As I just mentioned, we've completed the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot